scholarly journals Clinical pharmacist roles in primary care networks

Prescriber ◽  
2019 ◽  
Vol 30 (11) ◽  
pp. 22-26 ◽  
Author(s):  
Duncan Petty

2018 ◽  
Vol 2 (2) ◽  
pp. 123-130 ◽  
Author(s):  
Maja Kjaer Rasmussen ◽  
Lene Vestergaard Ravn-Nielsen ◽  
Marie-Louise Duckert ◽  
Mia Lolk Lund ◽  
Jolene Pilegaard Henriksen ◽  
...  


2019 ◽  
Vol 59 (3) ◽  
pp. 336-342
Author(s):  
Shubha Bhat ◽  
Miranda Kroehl ◽  
Whitley M. Yi ◽  
Jaclyn Jaeger ◽  
Angela M. Thompson ◽  
...  


2019 ◽  
Vol 33 (5) ◽  
pp. 654-660 ◽  
Author(s):  
Michael W. Nagy ◽  
Stephanie Gruber ◽  
Macy McConnell

Background: Recent literature findings suggest that opportunities exist to optimize testosterone replacement therapy management. Objective: To evaluate the impact of a pilot clinical pharmacist testosterone therapy management service in a Veterans Affairs primary care setting. Methods: A 6-month, single-clinic, prospective cohort quality improvement project included male patients with an active prescription for testosterone. Patients were excluded if they switched primary care providers or were managed by a specialty clinic. After diagnosis, primary care providers had the option of referring patients for clinical pharmacist testosterone replacement therapy management. The project investigated the impact of pharmacist management on adherence to guideline-defined baseline and therapeutic monitoring, prior authorization workload, time saved by primary care providers, and clinical pharmacist interventions. Results: Sixty patients split between pharmacist management (N = 35) and nonpharmacist management (N = 25) cohorts. Monitoring of baseline parameters was significantly improved with clinical pharmacist management (54% vs 20%, P = 0.0006). Improved baseline monitoring decreased prior authorization team workload as requests were approved on the first submission at a higher rate (100% vs 75.4%, P = 0.06). Pharmacist management increased therapeutic monitoring for assessing symptom improvement (96% vs 26%, P < 0.001), monitoring of testosterone levels (96% vs 61%, P = 0.003), and safety monitoring with complete blood counts (100% vs 83%, P = 0.04). A total of 42 pharmacist–patient encounters saved over 600 minutes of primary care provider time. Conclusion: Clinical pharmacist involvement enhances therapeutic monitoring for male hypogonadism leaving room for expansion of clinical pharmacy services within testosterone replacement therapy management.



2020 ◽  
Vol 50 (4) ◽  
pp. 297-307
Author(s):  
Erica Y. Tong ◽  
Gail Edwards ◽  
Phuong Uyen Hua ◽  
Gary Yip


Rheumatology ◽  
2014 ◽  
Vol 53 (suppl_1) ◽  
pp. i32-i32
Author(s):  
Louise Maguire ◽  
Chris Ollershaw ◽  
Sharon Abdy ◽  
Mike Scott ◽  
Steve Turley ◽  
...  


Pharmacy ◽  
2020 ◽  
Vol 8 (1) ◽  
pp. 13
Author(s):  
Zahraa Jalal ◽  
Vibhu Paudyal ◽  
Shahad Al-Arkee ◽  
Gillian Dyson ◽  
John Marriott

Objective: to conduct a Patient and Public Involvement (PPI) focus group session. To help inform the design of a clinical pharmacy intervention in primary care for patients after a coronary event. Methods: this study followed a public involvement method. Community members of the public and community engaged research patients who had experienced myocardial infarction where invited to actively take part in a focus group discussion. This is to share past experiences and provide input and advice into the design of a potential research proposal. The session took place at a cardiac rehabilitation centre. Results: four key themes were identified from the focus group these included: experiences with pharmacy and primary care services, medicines knowledge, the pharmacist role and building rapport with healthcare professionals. Nine participants and three researchers attended the PPI discussion session. Seven of the participants were patients who had experienced a cardiac event in the last three months and two were carers. Primary care pharmacy services both clinical and public health were not very familiar to the participants. Different experiences with clinical pharmacy services were reported by participants, while one experience was reported to be helpful others perceived community pharmacists to be to be busy and isolated behind a counter. A general practice GP based specialist nurse was a familiar model of care unlike a specialist clinical pharmacist GP based care role. Participants reported limited time in GP consultations and the need to book double appointments. Participants stressed the need to receive consistent information about their disease and medication from different professionals involved in their care. Different views were expressed regarding the ability to build rapport with a clinical pharmacist when compared to a GP. Input on study outcomes and design was provided by participants. Conclusion: participants in this session mentioned that a clinical pharmacy intervention after hospital discharge would be useful for their continuity of care. Plans are in place to continue to involve patients and the public in the write up, ethics and dissemination of the potential clinical pharmacy proposal.



2010 ◽  
Vol 13 (7) ◽  
pp. A364
Author(s):  
N Triki ◽  
S Shani ◽  
D Rabinovich-Protter ◽  
D Mossinson ◽  
E Kokia ◽  
...  


2017 ◽  
Vol 78 (3) ◽  
pp. 181-185 ◽  
Author(s):  
Mollie Ashe Scott ◽  
Jeffrey E. Heck ◽  
Courtenay Gilmore Wilson




Sign in / Sign up

Export Citation Format

Share Document